WallStreetZenWallStreetZen

NASDAQ: GILD
Gilead Sciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for GILD

Based on 12 analysts offering 12 month price targets for Gilead Sciences Inc

Min Forecast
$118.00-23.86%
Avg Forecast
$151.50-2.25%
Max Forecast
$177.00+14.21%

Should I buy or sell GILD stock?

Based on 12 analysts offering ratings for Gilead Sciences Inc.

Strong Buy
Strong Buy
9 analysts 75%
Buy
2 analysts 16.67%
Hold
1 analysts 8.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Buy" agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their GILD stock forecasts and price targets.

GILD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-11
lockedlocked$00.00+00.00%2026-02-11Find Out Why
lockedlocked$00.00+00.00%2026-02-11Find Out Why
lockedlocked$00.00+00.00%2026-02-11Find Out Why
lockedlocked$00.00+00.00%2026-02-11
Needham
Top 1%
100
BuyMaintains$170.00+9.69%2026-02-11
Citigroup
Top 11%
90
Strong BuyMaintains$156.00+0.66%2026-01-27Find out why
UBS
Top 16%
85
Strong BuyMaintains$155.00+0.01%2026-01-26Find out why
Morgan Stanley
Top 22%
79
Strong BuyMaintains$150.00-3.21%2026-01-13
Truist Securities
Bottom 7%
7
Strong BuyReiterates$145.00-6.44%2025-11-03

1 of 2

Forecast return on equity

Is GILD forecast to generate an efficient return?

Company
64.56%
Industry
-52.98%
Market
236.84%
GILD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GILD forecast to generate an efficient return on assets?

Company
23.76%
Industry
25.46%
GILD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GILD earnings per share forecast

What is GILD's earnings per share in the next 3 years based on estimates from 30 analysts?

Avg 1 year Forecast
$8.92+37.01%
Avg 2 year Forecast
$9.62+47.75%
Avg 3 year Forecast
$10.28+57.94%
GILD's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

GILD revenue forecast

What is GILD's revenue in the next 3 years based on estimates from 32 analysts?

Avg 1 year Forecast
$30.8B+5.96%
Avg 2 year Forecast
$32.6B+12.12%
Avg 3 year Forecast
$34.0B+17.01%
GILD's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GILD earnings growth forecast

How is GILD forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
16.49%
Industry
30.93%
Market
39.72%
GILD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
GILD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
GILD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

GILD revenue growth forecast

How is GILD forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
5.46%
Industry
8.25%
Market
24.07%
GILD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GILD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GILD vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
GILD$154.98$151.50-2.25%Strong Buy
AMGN$369.19$346.15-6.24%Buy
PFE$27.58$28.29+2.56%Hold
BMY$60.74$60.18-0.92%Buy
GSK$58.93N/AN/A
View Top General Drug Manufacturer Stocks

Gilead Sciences Stock Forecast FAQ

Is Gilead Sciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 12 Wall Street analysts covering (NASDAQ: GILD) stock is to Strong Buy GILD stock.

Out of 12 analysts, 9 (75%) are recommending GILD as a Strong Buy, 2 (16.67%) are recommending GILD as a Buy, 1 (8.33%) are recommending GILD as a Hold, 0 (0%) are recommending GILD as a Sell, and 0 (0%) are recommending GILD as a Strong Sell.

If you're new to stock investing, here's how to buy Gilead Sciences stock.

What is GILD's earnings growth forecast for 2026-2028?

(NASDAQ: GILD) Gilead Sciences's forecast annual earnings growth rate of 16.49% is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 30.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.72%.

Gilead Sciences's earnings in 2026 is $8,110,000,000.On average, 30 Wall Street analysts forecast GILD's earnings for 2026 to be $11,066,241,897, with the lowest GILD earnings forecast at $7,757,225,275, and the highest GILD earnings forecast at $12,375,779,239. On average, 24 Wall Street analysts forecast GILD's earnings for 2027 to be $11,933,725,090, with the lowest GILD earnings forecast at $8,450,268,912, and the highest GILD earnings forecast at $14,577,365,230.

In 2028, GILD is forecast to generate $12,756,295,680 in earnings, with the lowest earnings forecast at $8,742,076,760 and the highest earnings forecast at $15,007,260,720.

What is GILD's revenue growth forecast for 2026-2028?

(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 5.46% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.07%.

Gilead Sciences's revenue in 2026 is $29,087,000,000.On average, 32 Wall Street analysts forecast GILD's revenue for 2026 to be $38,238,986,660,483, with the lowest GILD revenue forecast at $36,159,607,612,335, and the highest GILD revenue forecast at $40,168,243,474,248. On average, 30 Wall Street analysts forecast GILD's revenue for 2027 to be $40,462,284,544,899, with the lowest GILD revenue forecast at $37,396,565,196,466, and the highest GILD revenue forecast at $44,090,031,762,551.

In 2028, GILD is forecast to generate $42,227,771,648,428 in revenue, with the lowest revenue forecast at $37,392,843,157,597 and the highest revenue forecast at $46,612,333,436,110.

What is GILD's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: GILD) forecast ROA is 23.76%, which is lower than the forecast US Drug Manufacturers - General industry average of 25.46%.

What is GILD's Price Target?

According to 12 Wall Street analysts that have issued a 1 year GILD price target, the average GILD price target is $151.50, with the highest GILD stock price forecast at $177.00 and the lowest GILD stock price forecast at $118.00.

On average, Wall Street analysts predict that Gilead Sciences's share price could fall to $151.50 by Feb 11, 2027. The average Gilead Sciences stock price prediction forecasts a potential downside of 2.25% from the current GILD share price of $154.98.

What is GILD's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: GILD) Gilead Sciences's current Earnings Per Share (EPS) is $6.51. On average, analysts forecast that GILD's EPS will be $8.92 for 2026, with the lowest EPS forecast at $6.25, and the highest EPS forecast at $9.98. On average, analysts forecast that GILD's EPS will be $9.62 for 2027, with the lowest EPS forecast at $6.81, and the highest EPS forecast at $11.75. In 2028, GILD's EPS is forecast to hit $10.28 (min: $7.05, max: $12.10).

What is GILD's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: GILD) forecast ROE is 64.56%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.